scholarly article | Q13442814 |
P356 | DOI | 10.1002/ART.39039 |
P698 | PubMed publication ID | 25605003 |
P50 | author | Pier Luigi Meroni | Q38544871 |
Nicoletta Ronda | Q40083991 | ||
Francesca Zimetti | Q40351192 | ||
Maria Orietta Borghi | Q47504194 | ||
Ennio Giulio Favalli | Q51741925 | ||
Elda Favari | Q88828463 | ||
Franco Bernini | Q92546543 | ||
Rita Gatti | Q114294879 | ||
P2093 | author name string | Ivana Hollan | |
Knut Mikkelsen | |||
Maria Pia Adorni | |||
Daniela Greco | |||
Gunnbjørg Hjeltnes | |||
P433 | issue | 5 | |
P921 | main subject | lipoprotein | Q28350 |
macrophage | Q184204 | ||
adalimumab | Q348260 | ||
methotrexate | Q422232 | ||
P304 | page(s) | 1155-1164 | |
P577 | publication date | 2015-05-01 | |
P1433 | published in | Arthritis & Rheumatology | Q4797636 |
P1476 | title | Newly identified antiatherosclerotic activity of methotrexate and adalimumab: complementary effects on lipoprotein function and macrophage cholesterol metabolism | |
P478 | volume | 67 |
Q88461341 | Angiotensin receptor blocker vs ACE inhibitor effects on HDL functionality in patients on maintenance hemodialysis |
Q41143656 | Anti-inflammatory treatment improves high-density lipoprotein function in rheumatoid arthritis |
Q47168123 | Blood-brain barrier breakdown promotes macrophage infiltration and cognitive impairment in leptin receptor-deficient mice |
Q38737288 | Cardiac involvement in primary systemic vasculitis and potential drug therapies to reduce cardiovascular risk |
Q88917533 | Cardiovascular Safety of Biologics and JAK Inhibitors in Patients with Rheumatoid Arthritis |
Q40959053 | Effect of Drug Therapy on Net Cholesterol Efflux Capacity of High-Density Lipoprotein-Enriched Serum in Rheumatoid Arthritis |
Q47154672 | Effect of a novel nutraceutical combination on serum lipoprotein functional profile and circulating PCSK9. |
Q38680931 | High-density lipoprotein function in rheumatoid arthritis |
Q90250474 | IL-1 Inhibition and Function of the HDL-Containing Fraction of Plasma in Patients with Stages 3 to 5 CKD |
Q90389973 | Identifying the anti-inflammatory response to lipid lowering therapy: a position paper from the working group on atherosclerosis and vascular biology of the European Society of Cardiology |
Q52312175 | Increased cardiovascular risk in rheumatoid arthritis: mechanisms and implications. |
Q49721726 | Lipids in RA: Is Less Not Necessarily More? |
Q42682318 | Methotrexate and anti-tumor necrosis factor treatment improves endothelial function in patients with inflammatory arthritis |
Q36162860 | Patients with Rheumatoid Arthritis Show Altered Lipoprotein Profiles with Dysfunctional High-Density Lipoproteins that Can Exacerbate Inflammatory and Atherogenic Process |
Q40083837 | Plasma cholesterol homeostasis, HDL remodeling and function during the acute phase reaction. |
Q50055620 | Population Pharmacokinetics of High-Dose Methotrexate in Patients With Primary Central Nervous System Lymphoma |
Q49603124 | Potential of anti-inflammatory agents for treatment of atherosclerosis |
Q59135667 | Repurposing existing drugs for cardiovascular risk management: a focus on methotrexate |
Q38794852 | Rheumatoid Arthritis Pharmacotherapies: Do They Have Anti-Atherosclerotic Activity? |
Q60959818 | Targeting Inflammation to Prevent Cardiovascular Disease in Chronic Rheumatic Diseases: Myth or Reality? |
Q50109832 | The Impact of Biologics and Tofacitinib on Cardiovascular Risk Factors and Outcomes in Patients with Rheumatic Disease: A Systematic Literature Review |
Q36000249 | The challenging interplay between rheumatoid arthritis, ageing and comorbidities |
Q48227295 | Tofacitinib restores the inhibition of reverse cholesterol transport induced by inflammation: understanding the lipid paradox associated with rheumatoid arthritis |
Search more.